StockData
Pulmatrix, Inc. logo

Pulmatrix, Inc. (PULM) stock

PULMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$1.27−0.15 (-10.56%)

Close on Nov 20, 2026Market cap $4.64MP/E –Yield –

Pulmatrix free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Pulmatrix's free cash flow for the twelve months ending Dec 31, 2024 was -$11.11M. For fiscal 2024 it was -$11.11M. The highest annual figure on record is $3.17M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$11.11M–
FY2023Dec 31, 2023-$16.66M–
FY2022Dec 31, 2022-$19.44M–
FY2021Dec 31, 2021-$19.87M–
FY2020Dec 31, 2020-$12.76M-502.4%
FY2019Dec 31, 2019$3.17M–
FY2018Dec 31, 2018-$16.78M–
FY2017Dec 31, 2017-$14.55M–
FY2016Dec 31, 2016-$13.70M–
FY2015Dec 31, 2015-$12.74M–
FY2014Dec 31, 2014-$9.45M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024-$1.26M–
Q3 FY2024Sep 30, 2024-$3.06M–
Q2 FY2024Jun 30, 2024-$3.92M–
Q1 FY2024Mar 31, 2024-$2.87M–
Q4 FY2023Dec 31, 2023-$2.32M–
Q3 FY2023Sep 30, 2023-$4.46M–
Q4 FY2022Dec 31, 2022-$5.06M–
Q3 FY2022Sep 30, 2022-$3.60M–
Q2 FY2022Jun 30, 2022-$4.63M–
Q1 FY2022Mar 31, 2022-$6.15M–
Q4 FY2021Dec 31, 2021-$4.42M–
Q3 FY2021Sep 30, 2021-$3.41M-586.0%
Q4 FY2020Dec 31, 2020-$2.85M–
Q3 FY2020Sep 30, 2020-$5.62M–
Q2 FY2020Jun 30, 2020-$5.00M-133.3%
Q1 FY2020Mar 31, 2020$702.00K–
Q4 FY2019Dec 31, 2019-$4.44M–
Q3 FY2019Sep 30, 2019-$3.94M–
Q2 FY2019Jun 30, 2019$15.02M–
Q1 FY2019Mar 31, 2019-$3.47M–
Q4 FY2018Dec 31, 2018-$4.18M–
Q3 FY2018Sep 30, 2018-$4.53M–
Q4 FY2017Dec 31, 2017-$3.25M–
Q3 FY2017Sep 30, 2017-$4.64M–
Q4 FY2016Dec 31, 2016-$2.52M–

More Pulmatrix figures

See a number that looks wrong?